A plausible explanation for this lack of a significant difference between these groups is that it could be related to the natural history and the aggressive phenotype of our analysis cohort (metastatic disease requiring chemotherapy) with other genetic abnormalities beyond ALK gene copy number having a greater functional role in oncogenesis. This evidence concerns the gene ALK and metastatic neoplasm.